Bristol UFT/Orzel
Executive Summary
NDAs for UFT (tegafur/uracil) capsules for use with leucovorin in the first-line treatment of advanced colorectal cancer and Orzel (UFT capsules packaged with leucovorin tablets) are withdrawn. At a March 3 securities analyst conference, Bristol had said FDA's review was likely to be delayed (1"The Pink Sheet" March 13, p. 27). Bristol will refile the applications after FDA examines new data analyses
You may also be interested in...
Bristol To Focus On Paraplatin For Oncology Growth; UFT Review Delayed
Bristol-Myers Squibb is looking to Paraplatin (carboplatin) to lead oncology growth in the wake of a court decision opening the door to generic competition for its Taxol (paclitaxel) franchise.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials